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Background: Concern has been growing in the academic literature and popular media about the licensing,
introduction and adoption of surgical devices before full effectiveness and safety evidence is available to inform
clinical practice. Our research will seek empirical survey evidence about the roles, responsibilities, and information
and policy needs of the key stakeholders in the introduction into clinical practice of new surgical devices for pelvic
floor surgery, in terms of the underlying ethical principals involved in the economic decision-making process, using
the example of pelvic floor procedures.
Methods/Design: Our study involves three linked case studies using, as examples, selected pelvic floor surgery
devices representing Health Canada device safety risk classes: low, medium and high risk. Data collection will focus
on stakeholder roles and responsibilities, information and policy needs, and perceptions of those of other key
stakeholders, in seeking and using evidence about new surgical devices when licensing and adopting them into
practice. For each class of device, interviews will be used to seek the opinions of stakeholders. The following
stakeholders and ethical and economic principles provide the theoretical framework for the study:
Stakeholders - federal regulatory body, device manufacturers, clinicians, patients, health care institutions, provincial
health departments, and professional societies. Clinical settings in two centres (in different provinces) will be
included.
Ethics - beneficence, non-maleficence, autonomy, justice.
Economics - scarcity of resources, choices, opportunity costs.
For each class of device, responses will be analysed to compare and contrast between stakeholders. Applied ethics
and economic theory, analysis and critical interpretation will be used to further illuminate the case study material.
Discussion: The significance of our research in this new area of ethics will lie in providing recommendations for
regulatory bodies, device manufacturers, clinicians, health care institutions, policy makers and professional societies,
to ensure surgical patients receive sufficient information before providing consent for pelvic floor surgery. In
addition, we shall provide a wealth of information for future study in other areas of surgery and clinical
management, and provide suggestions for changes to health policy.
Background
A US Food and Drug Administration (FDA) public
health announcement, released to physicians in October
2008, highlighted concerns associated with the use of
licensed mesh devices in the minimally invasive surgical
repair of pelvic organ prolapse and stress urinary
incontinence. The announcement reported serious com-
plications resulting from the use of licensed devices
from nine manufacturers, and pointed out that some of
the complications led to significant decrease in patient
quality of life with ongoing symptoms. The FDA mem-
orandum stressed the need for surgeons to seek specia-
lized training for each type of technique, to be vigilant
about adverse events and complications, and highlighted
the importance of informing patients about the potential
for adverse events with possible long-term unpleasant
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any medium, provided the original work is properly cited.effects on quality of life [1]. The information in the FDA
announcement was reiterated in 2010 by the Health
Canada Marketed Health Products Directorate [2].
These unusual announcements underline the dangers
associated with the adoption of new licensed medical
devices, and provide a reminder that the responsibility
for patient outcome lies not only with regulators and
device manufacturers, but also with policy makers and
surgeons, and that patient should be active in the deci-
sion to have surgery performed.
The decisions surrounding the choice of medical
device to approve (by device regulators), fund (by health
care funding bodies) or adopt into clinical practice (by
hospital authorities and clinicians) are affected by many
different motivators and barriers, such as perceived
effectiveness, safety (as highlighted by the FDA and
Health Canada [1,2]), and also ethical and economic
considerations. The research described in this protocol
will examine specifically how ethics and economics
influence stakeholders’ decisions about adopting new
devices, particularly when full information on effective-
ness and safety may not be available.
In Canada, the licensing and use of new medical
devices occurs within a health care system in which the
adoption of new technologies is guided by ethics and eco-
nomics as well as by clinical investigation: assuming that
there is evidence that a new device is effective, the adop-
tion of that device is subject to ethical and economic
choices at all levels of the health care system. Ethics
influences such decisions, seeking assurance that the
device will benefit patients while not doing them dispro-
portionate harm, that individuals are fully informed
before they make decisions about adopting a new device,
and that risks and benefits of a new treatment (or from
withdrawing access to an older one) are fairly and rea-
sonably distributed [3]. Economic theory offers further
insights into the decision-making process, suggesting
that in situations of limited resources, choices are neces-
sary about which technologies should be adopted and
which services should be sacrificed in order to free up
resources [3-6]. Thus both ethics and economics are con-
cerned with making good choices in adopting new health
technologies, and may even be considered inseparable
[3-6]. They are as fundamental to decisions about licen-
sing and adopting new clinical devices, as considerations
of clinical effectiveness and safety.
Licensing medical devices in Canada
The introduction of new medical devices in Canada is
regulated by the Medical Devices Regulations of the
Food and Drugs Act [7]. The process is governed by the
Medical Device Regulatory Framework and undertaken
by the Medical Device Bureau (MDB, one of the
bureaux of the Health Canada Therapeutic Products
Division). The mandate of MDB is specifically to evalu-
ate and monitor the safety, efficacy and quality of diag-
nostic and therapeutic medical devices [8].
Manufacturers of medical devices require licenses to sell
their products in Canada [9]: each new surgical device is
classified according to risk, based on factors such as
degree of invasiveness, duration of contact with patient,
energy transmission hazard and consequences of device
malfunction or failure. Risk class (Table 1) is allocated
by comparing new devices to similar or competitive
devices [9].
The level and amount of evidence required for licen-
sing a specific new device (or group of devices) depends
on the classification of risk assigned to that device: the
greatest degree of rigour is required for evidence of
safety and efficacy in Class IV devices. Class I devices
do not remain in contact with the patient for long peri-
ods, so the risks are deemed low. Manufacturers of
Class I devices are not required to obtain licenses for
specific devices, but need only an “establishment license”
[9]. For new Class II to Class IV devices, licenses may
be approved without evidence of safety or effectiveness,
if the new device is “substantially equivalent” to a
licensed device, or is a “family member” of an already
licensed product [7,10]. The licensing regulations in the
USA and European Union are similar in allowing
approval without clinical testing [10,11].
Ethical issues associated with introducing new medical
devices
We recently discussed the ethical issues associated with
the introduction of new surgical devices, using new uro-
gynaecological devices as an example [12]. Our key con-
cern was that newer devices are being marketed at an
earlier stage in the development process, before ade-
quate research evidence of effectiveness and safety is
available to inform clinical practice.
Our study was novel in analysing the ethical issues
from six perspectives: MDB, device manufacturers,
Table 1 Medical Device Bureau classification of medical devices
MDB Class Risk Examples
Class I Lowest risk Surgical instruments, culture media
Class II Low risk Contact lenses, epidural catheters, pregnancy test kits, surgical gloves, ultrasound scanner
Class III Moderate risk Orthopaedic implants, glucose monitors, dental implants, haemodialysis systems
Class IV High risk HIV test kits, pacemakers, angiographic catheters
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sional societies. We found that, in the case of new
“family members” (i.e. new surgical devices made by a
manufacturer who already produces licensed devices for
the same clinical indication), rigorous evidence of safety
is not required for MDB to license the new device, even
t h o u g ht h eu s eo fs u c had e v i c em a yb ep o t e n t i a l l y
harmful to patients. The lack of clinical evidence
impacted on the ethical behaviour of all parties, calling
for particular care in making open disclosures of the
absence of information and experience. Our evaluation
concluded that, without more rigorous MDB require-
ments for safety and effectiveness information for licen-
sing devices, manufacturers and clinicians should aim
for higher ethical standards to protect the health and
safety of patients requiring surgical interventions. If not
required by MDB, manufacturers should cooperate with
physicians in designing and undertaking appropriate
clinical research, and should provide balanced presenta-
tions of all the available evidence (or lack if it). Before
using a new surgical device, clinicians should carefully
evaluate the available evidence of effectiveness and
safety and seek training in the use of the device. They
should provide patients with a careful evaluation of the
evidence and inform patients about their personal
experience with the new device. Patients should be
encouraged to decide themselves, based on full informa-
tion about the new device and their surgeon’se x p e r i -
ence, whether they wish to receive the new device. We
also suggested that MDB should require rigorous clinical
trial evidence before licensing new family members,
similar to the level of evidence required for licensing
new types of device [12].
Economic issues
Our preliminary evaluation raised a number of unan-
swered questions. In particular, we did not consider the
economic perspective that would focus on exploring
whether the adoption of a new procedure, for which
effectiveness and safety have not been adequately estab-
lished, would represent efficient use of limited societal
resources. In addition, we did not consider the opportu-
nity costs to Health Canada and the device manufac-
turers of increasing the level of evidence required for
licensing new devices. Further our evaluation was not
sufficiently detailed to define the important ethical and
economic questions in regulating medical devices.
Much published literature describes the issues surround-
ing ethics, economics and regulation and adoption of
drugs [13-19]. Little comparable work has examined these
issues in relation to the regulation and adoption of medical
devices, although several authors have pointed out the
paucity of health economics and ethics support for health
technology assessments of medical devices [20-22].
The disciplines of ethics and economics offer comple-
mentary insights into the decision-making context, and
our proposed study will therefore undertake a detailed
examination of the regulation and introduction of new
medical devices into clinical practice, integrating ethical
and economic principles to guide the work.
Research Question
What are the roles, responsibilities, and information and
policy needs of the key stakeholders in the introduction
into clinical practice of new surgical devices, in terms of
the underlying ethical principles involved in the eco-
nomic decision-making process, using the example of
pelvic floor procedures?
Methods/Design
The proposed study will consist of three linked case stu-
dies using, as examples, selected pelvic floor surgery
devices representing Health Canada device safety risk
classes: low risk (eg suture capturing device), moderate
risk (eg mesh device for pelvic organ prolapse repair)
and high risk (eg implantable sacral nerve stimulator).
Data collection will focus on stakeholder roles and
responsibilities, information and policy needs, and per-
ceptions of those of other key stakeholders, in seeking
and using evidence about new surgical devices when
licensing and adopting them into practice. For each
class of device, interviews will be used to survey the jud-
gements and experiences of stakeholders. The study will
be undertaken as an investigation of the conduct and
beliefs of the stakeholders from their perspective, but
will also use applied ethics and economics theories,
arguments and analyses to illuminate the case studies.
E t h i c a la p p r o v a lf o rt h es t u d yw a sr e c e i v e df r o mt h e
University of Calgary Conjoint Health Research Ethics
Board (E-22708).
Clinical setting
For this study, we have chosen to concentrate on medi-
cal devices used in female pelvic floor surgery, to ensure
we examine the differences and similarities in ethical
and economic considerations that relate to differing
classes of device, rather than issues that relate to differ-
ences between surgical specialties. Urogynaecology sur-
gery, although a subspecialty of obstetrics and
gynaecology, is typical of other surgical specialties which
include non-emergency elective surgery.
Pelvic floor disorders (urinary incontinence, fecal
incontinence, and pelvic organ prolapse, where pelvic
organs bulge into the vagina) are common, affecting at
least a third of adult women of all ages [23]. Surgical
procedures for pelvic floor disorders are among the
most common of all female surgeries [24]. The lifetime
risk of undergoing at least one operation for prolapse or
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at least one re-operation) [25]. The growth in demand
for pelvic floor disorder services is expected to increase
at twice the rate of population increase, because of the
increasing demand for services in women over 60 years
of age [26]. Further, the aging “baby boomers” are likely
to be more demanding than previous generations [26].
This increasingly important surgical market is seeing
intensifying competition between the device manufac-
turers, leading to a growth in the number of new and
minimally invasive surgical devices being developed and
marketed.
Expansion in demand for treatments, and concern
about the introduction of new technologies, have led to
consideration of ethical issues in other surgical areas.
For example, there are publications relating to neurosur-
gery [27], orthopaedics [28], and spine surgery [29], that
suggest the issues in other surgical specialties are similar
to those experienced in urogynaecology, particularly
among surgical procedures that are elective. Similar con-
siderations will apply to non-emergency general surgical
procedures such as groin hernia repair and cholecystect-
omy, although we have not found an examination of the
ethical or economic issues associated with the introduc-
tion of new devices in these clinical areas.
Devices
For the purpose of this study, we have chosen three spe-
cific devices used in urogynaecology, one for each of the
more invasive MDB classes (ie one for each case study)
(Table 2). Class I devices will not be included in our
study because device manufacturers are not required to
obtain individual licences for them, and therefore the
licensing requirements and adoption practices are very
different.
The choice of these specific devices is based on the
premise that slightly older examples are needed for this
study, in order that we can examine the types of infor-
mation that institutions and policy makers used to
decide whether to adopt them into practice. Extremely
new devices may not have yet found their way into
widespread use, and would be less likely to have under-
gone a thorough evaluation process.
Stakeholders
Seven groups of stakeholders will be considered for each
c a s es t u d y .T h eg r o u p sa r et h o s ew ei d e n t i f i e df o ro u r
initial investigation of the ethical issues associated with
the introduction of new surgical devices: regulatory
bodies, device manufacturers, clinicians, patients, health
care institutions and professional societies [12]. These
groups of stakeholders are similar for the adoption of
any surgical device into clinical practice, whether urogy-
naecology, neurosurgery, general surgery or orthopae-
dics [26-28]. We have also included provincial health
departments, because these stakeholders are responsible
for health care budgets within provinces, and several
provinces have established health technology assessment
programs to evaluate new medical devices.
Principles underlying the study
Ethics and economics are the two disciplines that pro-
vide the principles that together underpin this study.
The study will be undertaken as an investigation of the
conduct and perceptions of the stakeholders using in-
depth qualitative interviews. The goal of the research
is to provide a rich description of the medical device
approval process in the cases considered here, and to
begin a public discussion of the strengths and limita-
tions of that process. The interviews will be semi-
structured to allow for questions and later analysis
related to the ethics and economics principles detailed
below. We do not expect each interview respondent or
stakeholder group to necessarily or explicitly address
these principles. The interview format also allows for
respondents to introduce concepts or understandings
about the medical device approval process that we
have not anticipated. However, we expect at the end of
t h ei n t e r v i e wp r o c e s st ob ea b l et od i s c u s st h ee x t e n t
to which the following ethical principles and economic
principles bear upon the approval and use of the
selected medical devices. Given the resource con-
straints of the health care system, the ethical principles
cannot be examined in isolation: both ethics and eco-
nomics must be addressed together when assessing to
what extent reasoned approaches are being taken
toward the public good [3]. It is important to identify
the relevant ethical and economic principles before
starting the research.
Ethical principles
Four medical ethics principles [3] relevant to the intro-
duction of new surgical devices, will be discussed for
each case study, based on our earlier investigation [12]:
Beneficence, in the context of this study, is the
obligation “to provide benefit” to patients [3]
in part by ensuring that treatments are effective.
Table 2 Medical devices selected for case study
MDB
Class
Device selected for study Year first licensed
Class II Suture capturing device - first licensed in
1999
Class III Mesh device for pelvic organ prolapse
repair
- first licensed in
2005
Class IV Implantable sacral nerve stimulator - first licensed in
1999
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harm“ [3] on patients (unless this is outweighed by
potential benefit to the patient), in part by provid-
ing safe treatments. Beneficence and non-malefi-
cence are inter-related and may be discussed
together. In the proposed study, the type and
degree of beneficence and non-maleficence vary
according to the relationship between specific sta-
keholders (and their roles) and the patient (or
patients). For example, a commonly discussed rela-
tionship in medical ethics is that of physician and
patient. In this relationship, beneficence is assumed
to involve promoting the welfare of specific
patients, while non-maleficence is assumed to keep
them from harm. In contrast, the discussion of
beneficence and non-maleficence as related to the
relationship between a health authority and the
patients in their region, is also influenced by the
need to provide benefit to large numbers of
patients with conflicting conditions and needs. The
situation relating device manufacturers and patients
is clearly even more complex, given that there is
not a direct relationship with a specific patient (or
specific groups of patients), rather overall obliga-
tions of beneficence and non-maleficence directed
at patients generally. Further the relationship is
conflicted by the obligation to provide profit to the
company owners, which influences all aspects of
device manufacturers’ conduct.
Respect for autonomy upholds the patient right of
self-determination, the “right to hold views, to make
choices, and to take actions based on personal values
and beliefs“ [3]. Such choices include the right to
make informed choices about treatment. Doctors
also make autonomous decisions, providing the
treatment they believe is clinically appropriate, based
on patient need, and availability of treatments and
resources [3,30]. Thus conflict may occur between
respect for the patient’s autonomy and the physi-
cian’s obligation to act in ways he or she believes
will be for the patient’s medical benefit. Of impor-
tance in any discussion about autonomy is the need
for patients to be fully informed about the conse-
quences of any treatment choice: in discussions
about adoption of new devices into practice, such
discussions must include information about lack of
evidence, as well as information about outcomes of
treatment. As yet, we do not know how much infor-
mation patients need about the safety and effective-
ness of medical devices, how much information
physicians give, or whether patients receive the
information they need or desire.
Justice may be interpreted as “fair, equitable, and
appropriate treatment in light of what is due or
owed to persons“ [3]. It is relevant to fair access to
treatment, responsible stewardship of scarce
resources, and compensation for injury. Conflicts
can occur between an individual patient’s needs and
the needs of larger groups of patients (for example a
hospital’s patients, or patients in a province) where
access to a particular type of treatment may be
restricted as a result of limited resources.
Thus the ethical perspective within the context of
health care provision changes depending on specific
relationships between stakeholders and patients. How-
ever, these ethical relationships are not unique to urogy-
naecology: rather the situations observed in
urogynaecology are representative of other surgical spe-
cialties and subspecialties.
Economic principles
The main economic principles to be examined are those
concerned with the introduction of new technologies
into a healthcare market [31].
Scarcity of resources
Resources are limited in the health care system, both
within urogynaecology itself, and more widely within
institutions and provincial health care [31]. Allocation
of scarce resources within drug treatment budgets is
well defined: drugs may be paid for within provincial
health care systems only if they are included within
provincial drug benefit programs [32,33]. Payment for
surgical procedures is also determined provincially,
but the situation for specific surgical devices depends
on local decisions by individual institutions, at hospi-
tal or regional health authority level. Deliberations
about allocation of scarce resources may be enhanced
by the availability of relevant health technology
assessments.
Choice
In situations involving limited resources, demand may
outstrip supply, therefore choices need to be made to
allocate them [34]. Choices relating to specific surgical
devices are made locally, by hospitals or regional health
authorities, based on evidence from manufacturers, clin-
icians and health technology evaluations (if available).
Even if a new device has clear evidence of benefit, it is
possible that a hospital will choose not to adopt it
because of resource constraints. Budgetary choices will
be made in the context of hospital, health authority or
provincial resources, and choices between clinical areas
(and type of patient) may be extremely difficult. Such
decisions may potentially lead to equity issues if
resources are available only in selected institutions or to
specific patients.
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These describe the cost of actions that lead to opportu-
nities forgone [34,35]. Local choices regarding specific
medical devices may depend on the need to divert
resources from one budgetary area to another. In the
case of urogynaecology, choices may impact on other
surgical procedures within gynaecology, may impact on
other surgical specialties, or more generally on the
health budget. The evaluation of opportunity costs in
the context of limited resources may have significant
impact on choice in health care settings [36].
In the setting of urogynaecology device licensing, mar-
keting and use, discussion of these economic principles
will contrast widely between the individual stakeholders.
Economic principles cannot be discussed in isolation:
the disciplines of ethics and economics are fundamental
to the allocation of scarce resources and fairness to
patients [3,5], alongside the assessment of clinical
effectiveness.
Interviews with stakeholders
Stakeholder interviews will be approached using an in-
depth, semi-structured approach. The interviews will
have some prepared, open-ended questions (with
probes and follow-ups also prepared to focus the inter-
view when needed), but respondents will also be able
to introduce issues and concerns not included in the
interview guide. Therefore, although the researchers
are entering the interview conversation with a partial
conceptual framework based upon the ethical and eco-
nomic principles defined above, the interview guides as
well as final analysis will evolve from the collection
and interpretation of the data. In addition, the inter-
views will focus on two inter-related but analytically
distinct dimensions: the respondents’ descriptions of
the current process through which the selected medi-
cal devices are approved and put into practice (for
each class of device, as relevant to respondent), and
their feelings or perceptions about that process and
how it might be improved. For instance, what are the
roles and responsibilities of various stakeholders in the
process? What kind of information do they have at
hand for decision-making and what kind of informa-
tion or policy do they think they need? Stakeholder-
specific interview schedules will be developed:
interviews will be in-depth guided by the interview
schedule.
Despite the in-depth nature of the interviews, this type
of interviewing should still be called “investigative inter-
viewing” b e c a u s et h et o p i ch a saf a i r l yn a r r o ws c o p e
(how new medical devices come into practice) and
f o c u s e so ne v e n t sa n dp r o c e s s e s( r a t h e rt h a n ,f o r
instance, cultural meanings, life histories, or theory ela-
boration) [37]. In-depth interviews are a suitable
approach for this study, since the stakeholders inhabit
different work and life settings with very different per-
spectives and priorities in relation to licensing and
adopting new medical devices. Such perspectives are dif-
ficult to capture using standardized survey or interview
instrument.
Interviews will be conducted face-to-face in the office
of the interviewee. They will be scheduled to take an
hour, and be audio recorded and transcribed, with field
notes taken by the interviewer. Interviews will be con-
ducted for each of the stakeholder groups listed overleaf.
The researchers will stop interviewing when either there
are no appropriate respondents remaining in the stake-
holder group (which will happen when the group is
quite small), or when respondents within each group
begin to substantially duplicate the answers other
respondents have already given. The latter is known as
the “saturation point.”
In terms of coding and analysis of the interview data,
the goal of the research is to examine the responses
from all the stakeholder groups and identify similarities
and differences within and between their accounts
[38,39]. The researchers will be able to report their
ideas about problems with the current process and
potential solutions, but will also be in a position to form
initial, normative interpretations of potential weaknesses
in the system based on an analysis of all the interviews.
Juxtaposing the interviews from the different stakeholder
groups also enables the researchers to identify and per-
haps explain differing perceptions of the actual process
by which medical devices are licensed, regulated and put
into practice in Canada, as well as potential obstacles to
improving that process.
The following individual stakeholders will be
approached for interview.
Representatives from Health Canada’sM D B
Representatives of the MDB, the Device Licensing Ser-
vices Division, and Marketed Health Products Directo-
rate will be invited to comment on the current and
evolving position of Health Canada in relation to the
regulation of new devices.
Representatives of device manufacturers
Product development and marketing leaders from the
relevant device manufacturers, will be interviewed about
the roles, responsibilities, and information and policy
needs believed to be important when introducing new
medical devices.
Clinician representatives
Clinicians from urogynaecology divisions in two Cana-
dian provinces will be asked to describe the system for
adopting new technologies in their institution, and
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devices.
Patient representatives
Patients recruited from pelvic floor clinics in two Cana-
dian provinces, will be interviewed to determine the
information patients expect would be available for new
medical devices used in urogynaecology, and who
should be providing and evaluating the information.
Health care institution representatives
Individuals responsible for overseeing the introduction
of new surgical technologies (for example, executive
chairs of new technology committees, heads of Depart-
ments of Obstetrics and Gynaecology and Surgery) in
two Canadian provinces, will be interviewed about the
roles, responsibilities, and information and policy needs
believed by the interviewees to be important when
introducing new medical devices.
Provincial health departments
Representatives of the two Canadian provincial health
departments who are responsible for consultation on new
medical devices will be interviewed, about the roles,
responsibilities, and information and policy needs believed
to be important when introducing new medical devices.
Professional societies
Key individuals in professional societies and associations
representing the Canadian medical device industry will
be interviewed about the perceived role of these socie-
ties in the introduction of new medical devices.
Data analysis
Data analysis will be undertaken for each group of sta-
keholders, taking the perspective of that stakeholder.
Analyses will be conducted by first reading and re-read-
ing the transcribed interviews, seeking to understand
stakeholders’ views of the roles, responsibilities, and
information and policy needs believed by the intervie-
wees to be important when introducing new medical
devices. Views of their own and other stakeholders’
roles will be important to incorporate. After achieving
familiarity with the data, analysis codes will be assigned
to the transcribed text, and analysis will seek to identify
themes that are relevant to the study [28]. An analysis
will be conducted for each class of device and each type
of stakeholder.
Synthesis and interpretation of information from the case
studies
One final report will be prepared for each class of
device, with stakeholder issues discussed for each device.
For each class of device, a descriptive subsection will
examine the stakeholders’ roles, responsibilities, and
information and policy needs in adopting new devices
into clinical practice. Applied ethics theory, analysis and
critical interpretation will be used to further illuminate
the case study material.
Stakeholders are likely to have contrasting and com-
peting ethical and economic perspectives, particularly
with regard to the higher risk categories of surgical
devices. The goal of the study is not to reconcile these
approaches, but rather to understand how they interact,
and how they influence the activities of the stakeholders.
Final reports for each device class will include descrip-
tions of the ethical and economic considerations that
impact on the regulation and adoption of such devices
into clinical practice, and will, if possible, also make
recommendations for future conduct of stakeholders.
Discussion
The main value of this research will be to describe the
current situation as it relates to the adoption of new
surgical devices into clinical practice in Canada. It
appears from our initial analysis that, in a rapidly devel-
oping area of surgical treatment, the regulation and
adoption of new devices is only partially guided by ethi-
cal considerations [12]. Further, different stakeholders
have different perspectives and goals. Thus a compre-
hensive investigation is required to identify the impor-
tant ethical and economic issues that guide the
behaviours of stakeholders including manufacturers, reg-
ulators, clinicians and patients. The proposed research
will provide that comprehensive analysis.
Although the research will be undertaken in Canada,
given the similarity between the regulatory requirements
in the USA and European community, the findings of
the study will be relevant to other jurisdictions.
The research will highlight possible deficiencies in the
current system of regulation and adoption of new medi-
cal devices. For example, it is possible that the research
will find that MDB does not widely communicate its
role in the regulation of medical devices, and that there-
fore MDB is perceived by stakeholders as being more
“responsible” for the safety of therapeutic medical
d e v i c e st h a ni sc u r r e n t l yp o s s i b l eb a s e do ne c o n o m i c
constraints. If the research does identify such a problem,
improvement in communication about MDB’sr o l em a y
increase the level of understanding by clinicians and
patients. Another example might be that physician com-
munication with patients about the level of evidence
and experience with new devices is lacking. If this
proves to be the case, then further research will be
undertaken to determine what type of communication is
best under such circumstances.
The research will provide evidence by which to guide
future behaviour of stakeholders, either by changing the
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example in seeking robust evidence before adopting a
new medical device), or else by changing behaviours to
communicate and highlight the true availability of evi-
dence of safety and effectiveness. The final stage of the
research will consist of a dissemination phase, during
which the research team will communicate the findings
of the research widely to stakeholders.
Thus we believe the value of the research findings can
be leveraged by knowledge translation into improved
practice (if necessary) by the stakeholders, as well as
further research in an underdeveloped research area.
Acknowledgements
The study is funded by the Canadian Institutes of Health Research. The
funding body had no role in the study design, and will have no role in the
conduct of the study, or decision to submit any manuscripts for publication.
Author details
1Department of Obstetrics and Gynaecology, University of Calgary, Calgary,
Canada.
2Department of Surgery, University of Calgary, Calgary, Canada.
3Departments of Community Health Sciences and Family Medicine,
University of Calgary, Calgary, Canada.
4Departments of Philosophy and
Medicine, Joseph L. Rotman Institute of Science and Values, University of
Western Ontario, London, Canada.
5Department of Clinical Epidemiology and
Biostatistics and the Centre for Health Economics and Policy Analysis,
McMaster University, Hamilton, Canada.
6Department of Sociology, University
of Calgary, Calgary, Canada.
Authors’ contributions
SR played a major role in the conception and design of the study. She will
lead the study, will be involved in interviewing participants, and will
undertake analysis and interpretation of data. CW played a major role in the
conception and design of the study. He will lead the ethics aspects of the
study. AG played a major role in the conception and design of the study.
He will lead the economic aspects of the study. AD played a major role in
the design of the study. She will provide the qualitative and ethnographic
expertise. She will be involved in the collection, analysis, and interpretation
of data. CT played a major role in the design of the study. She will be
involved in the collection, analysis, and interpretation of data. RL played a
major role in the design of the study. His expertise spans clinical, policy
making and knowledge transfer interests, and he will lead the study in these
areas. All authors have read and given final approval of the manuscript as
submitted.
Authors’ Information
SR is a health services researcher and Director of Research in the University
of Calgary Department of Obstetrics and Gynaecology. CW is a research
ethicist and Canada Research Chair in the Department of Philosophy at the
University of Western Ontario, and Director of the Joseph L Rotman Institute
of Science and Values. AG is a health economist and Professor in the
Department of Clinical Epidemiology and Biostatistics at McMaster University.
AD is a sociologist and Assistant Professor in the University of Calgary
Department of Sociology, and specializes in the social science of medical
knowledge and technologies, health care policy and political economy. CT is
a graduate student in Applied Psychology at the University of Calgary. RL is
a general surgeon, and Professor in the Department of Surgery at the
University of Calgary. He is a past President of the Canadian Association of
General Surgeons (CAGS).
Competing interests
The authors declare that they have no competing interests.
Received: 20 July 2010 Accepted: 26 August 2010
Published: 26 August 2010
References
1. FDA: FDA Public Health Notification: Serious Complications Associated
with Transvaginal Placement of Surgical Mesh in Repair of Pelvic Organ
Prolapse and Stress Urinary Incontinence. 2008 [http://www.fda.gov/
MedicalDevices/Safety/AlertsandNotices/PublicHealthNotifications/
ucm061976.htm], (accessed 17 November 2009).
2. Health Canada Marketed Health Products Directorate: Complications
Associated with Transvaginal Implantation of Surgical Mesh for the
Treatment of Stress Urinary Incontinence and Pelvic Organ Prolapse.
2010 [http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/_2010/
surgical-mesh_nth-aah-eng.php], (accessed 12 February 2010).
3. Beauchamp TL, Childress JF: Principles of biomedical ethics Oxford: Oxford
University Press, fifth 2001.
4. Williams A: The economic role of health indicators. In Measuring the Social
Benefit of Medicine. Edited by: Teeling Smith G. London: Office of Health
Economics; 1983:63-67.
5. Gafni A, Birch S: Incremental cost-effectiveness ratios (ICERs): the silence
of the lambda. Soc Sci Med 2006, 62(9):2091-100.
6. Birch S, Gafni A: The biggest bang for the buck or bigger bucks for the
bang: the fallacy of the cost-effectiveness threshold. J Health Serv Res
Policy 2006, 11(1):46-51.
7. Department of Justice Canada: Food and Drugs Act, Medical Devices
Regulations (SOR/98-282) [http://laws.justice.gc.ca/en/showtdm/cr/SOR-98-
282//?showtoc=&instrumentnumber=SOR-98-282], (accessed 17 November
2009).
8. Medical Devices Program: Strategic Plan 2007-2012: Building for the Future
[http://www.hc-sc.gc.ca/dhp-mps/pubs/md-im/mdp_pmm_plan_strat/index-
eng.php], (accessed 17 November 2009).




10. Lenzer J: Watching over the medical device industry. BMJ 2009, 338:
b2321.
11. Health Canada: Discussion Paper for Consultation: Proposed Changes to the
Regulatory Framework for Investigational Testing of Medical Devices [http://
www.hc-sc.gc.ca/dhp-mps/md-im/activit/consultation/pcitmd_cpreeim-eng.
php#1], (accessed 17 November 2009).
12. Ross S, Robert M, Harvey M-A, Farrell S, Schulz J, Wilkie D, Lovatsis D, Epp A,
Easton B, McMillan B, Schachter J, Gupta C, Weijer C: Ethical issues
associated with the introduction of new surgical devices: or just
because we can doesn’t mean we should. J Obstet Gynaecol Can 2008,
30(6):508-513.
13. Avorn J: Keeping science on top in drug evaluation. N Engl J Med 2007,
357(7):633-5.
14. Gagnon MA, Lexchin J: The cost of pushing pills: A new estimate of
pharmaceutical promotion expenditures in the United States. PLoS Med
2008, 5(1):e1.
15. Krumholz HM, Ross JS, Presler AH, Egilman DS: What have we learnt from
Vioxx? BMJ 2007, 334(7585):120-3.
16. Ogbogu U: Canada’s approach to conflict-of-interest oversight. CMAJ
2007, 177(4):375-6.
17. Steinbrook R: Financial conflicts of interest and the Food and Drug
Administration’s Advisory Committees. N Engl J Med 2005, 353(2):116-8.
18. Lo Re V, Strom BL: The role of academia and the research community in
assisting the Food and Drug Administration to ensure U.S. drug safety.
Pharmacoepidemiol Drug Saf 2007, 16(7):818-25.
19. Weijer C, Miller PB: When are research risks reasonable in relation to
anticipated benefits? Nature Medicine 2004, 10:570-573.
20. Bridges J: What can economics add to health technology assessment?
Please not just another cost-effectiveness analysis! Expert Rev
Pharmacoecon Outcomes Res 2006, 6(1):19-24.
21. Lehoux P, Williams-Jones B: Mapping the integration of social and ethical
issues in health technology assessment. Int J Technol Assess Health Care
2007, 23(1):9-16.
22. Tarride JE, McCarron CE, Lim M, Bowen JM, Blackhouse G, Hopkins R,
O’Reilly D, Xie F, Goeree R: Economic evaluations conducted by Canadian
health technology assessment agencies: where do we stand? Int J
Technol Assess Health Care 2008, 24(4):43-444.
23. Minassian V, Drutz H, Al-Badr A: Urinary incontinence as a worldwide
problem. Int J Obstet Gynecol 2002, 82:327-338.
Ross et al. BMC Medical Ethics 2010, 11:14
http://www.biomedcentral.com/1472-6939/11/14
Page 8 of 924. Waetjen L, Subak L, Hui S, Feng L, Tsung- His W, Vittinghoff E, Brown J:
Stress urinary incontinence surgery in the United States. Obstetrics and
Gynecology 2003, 101:671-676.
25. Olsen AL, Smith VJ, Bergstrom JO, Colling JC, Clark AL: Epidemiology of
surgically managed pelvic organ prolapse and urinary incontinence.
Obstet Gynecol 1997, 89(4):501-6.
26. Luber KM, Boero S, Choe JY: The demographics of pelvic floor disorders:
current observations and future projections. Am J Obstet Gyecol 2001,
184:1496-503.
27. Bernstein M, Bampoe J: Surgical innovation or surgical evolution: an
ethical and practical guide to handling novel neurosurgical procedures.
J Neurosurg 2004, 100(1):2-7.
28. Lieberman JR, Wenger N: New technology and the orthopaedic surgeon:
are you protecting your patients? Clin Orthop Relat Res 2004, , 429: 338-41.
29. Winter RB: Innovation in surgical technique: the story of spine surgery.
Clin Orthop Relat Res 2000, 378:9-14.
30. BMA Ethics Department: Medical ethics today: its practice and philosophy: the
BMA’s handbook of ethics and law London: BMJ Books, 2 2003.
31. Gafni A, Birch S: Guidelines for the adoption of new technologies: a
prescription for uncontrolled growth in expenditures and how to avoid
the problem. CMAJ 1993, 148(6):913-7.
32. Laupacis A: Inclusion of drugs in provincial drug benefit programs: who
is making these decisions, and are they the right ones? JAMC 2002,
166(1):44-7.
33. Gafni A, Birch S: Inclusion of drugs in provincial drug benefit programs:
should “reasonable decisions” lead to uncontrolled growth in
expenditures? CMAJ 2003, 168(7):849-51.
34. Sendi P, Al MJ, Gafni A, Birch S: Optimizing a portfolio of health care
programs in the presence of uncertainty and constrained resources. Soc
Sci Med 2003, 57(11):2207-15.
35. Jefferson T, Demicheli V, Mugford M: Elementary economic evaluation in
health care London: BMJ Publishing Group 1996.
36. Sendi P, Gafni A, Birch S: Opportunity costs and uncertainty in the
economic evaluation of health care interventions. Health Econ 2002,
11(1):23-31.
37. Rubin H, Rubin I: Qualitative Interviewing: The Art of Hearing Data Thousand
Oaks, CA, Sage Publications, 2 2005.
38. Strauss A: The Discovery of Grounded Theory Chicago, Aldine 1967.
39. Strauss A, Corbin J: Basics of Qualitative Research: Techniques and Procedures
for Developing Grounded Theory London, Sage Publications, 2 1998.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1472-6939/11/14/prepub
doi:10.1186/1472-6939-11-14
Cite this article as: Ross et al.: Ethics, economics and the regulation and
adoption of new medical devices: case studies in pelvic floor surgery.
BMC Medical Ethics 2010 11:14.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Ross et al. BMC Medical Ethics 2010, 11:14
http://www.biomedcentral.com/1472-6939/11/14
Page 9 of 9